Figure 5.

Functional assessment of the difference in drug sensitivity. (A) Isolated from hGBM-L0, SCCs and CD133^high cells were co-cultured and treated with TMZ. (B) Three days after initiating TMZ treatment, cell death was evaluated by flow cytometry using live/dead dye incorporation assay. Mean +/− SEM. One-way ANOVA. p-values were adjusted for multiplicity using the Bonferroni method. Results indicate distinct TMZ sensitivity between SCCs and CD133^high cells. Three days (C) and ten days (D) after TMZ treatment, the ratio SCC/CD133 was compared between the experimental conditions. Results show a significant increase in the ratio, indicating a greater resistance to TMZ of SCCs compared to CD133^high cells. Mean +/− SEM. One-way ANOVA. p-values were adjusted for multiplicity using the Bonferroni method. (E) Representative micrographs of co-cultured SCCs and CD133⁺ cells treated with TMZ. Scale bars, 100 µm. (F) Hierarchical clustering using DEGs between SCCs and CD133^high cells. (G) Drug target enrichment score between SCC and CD133^high groups. Drug IDs in red are agents specific to SCC. Drug IDs in yellow are specific to CD133^high cells. Drug ID: DB06245: Lanoteplase; DB00031: Tenecteplase; DB06157: Istaroxime; DB06550: Bivatuzumab; DB08515: (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL) (HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE; DB04141: 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol; DB04799: 6-Hydroxy-5-undecyl-4,7-benzothiazoledione; DB07401: Azoxystrobin; DB07763: (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE; DB07778: (S)-famoxadone; DB08330: METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE; DB08453: 2-Nonyl-4-quinolinol 1-oxide; and DB08690:Ubiquinone Q2.